Apostele

Apostele’s platform, TeleClinical Care (TCC), provides at-home support for patients who require neonatal intensive care or those with heart failure, gestational diabetes, and other chronic conditions. Patients interact with TCC through their phone or tablet, and TCC connects to peripheral devices to record blood pressure, pulse oximetry, weight, and other metrics, which are sent to clinicians in a Central Monitoring Centre (CMS). The CMS can then prioritise patients who need clinical review or intervention, improving outcomes and preventing unnecessary returns to hospital.

• Public health systems struggle to support patients living with complex and chronic disease, often resulting in unnecessary or unplanned hospitalisation.
• Without proper support, these patients consume excessive healthcare resources and have worse outcomes. In the most extreme cases, it leads to death in areas that could be avoided, such as heart failure.

• Initial market is local health districts, then private hospitals and health insurers
• Apostele has four technology companies that would like to white-label the portal

• Target sales revenue for FY 2025 is AUD1 million+
• Deployed in health service and has supported >9,000 patients
• Co-designed with clinicians, health executives, and patients